Investigating how certain bacteria cause infections and resist antibiotics
Official title: Administrative Supplement Equipment Request
Funded at Georgia Institute of Technology · NIH-11098834 · Data updated 2026-11-12
This study is looking at how certain harmful bacteria stick to our bodies and avoid our immune system, with the hope of finding new ways to prevent infections and improve treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $220,000 |
| NIH project number | 3R01GM148586-02S1 |
| Project ID | NIH-11098834 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by Gram-negative bacteria, particularly those with antibiotic-resistant strains.
✕Less likely to help
Patients with infections caused by Gram-positive bacteria or those not affected by antibiotic resistance may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms by which pathogenic Gram-negative bacteria, responsible for millions of deaths each year, cause infections and resist antibiotic treatment. It aims to explore specific proteins called autotransporters that help these bacteria adhere to host cells and evade the immune system. By studying how these proteins fold and function, the research seeks to identify new strategies for preventing bacterial infections and reducing antibiotic resistance. Patients may benefit from improved treatment options if successful.
Why it matters
Potential benefit: If successful, this research could lead to new methods for controlling bacterial infections and reducing antibiotic resistance, ultimately saving lives.
How similar studies have gone: Previous research has shown promise in targeting bacterial autotransporters, indicating that this approach could lead to significant advancements in infection control.
Where this research is happening
-
Georgia Institute of Technology
Atlanta, United States Active
Researchers
- Principal investigator: Gumbart, James C. — Georgia Institute of Technology
- Study coordinator: Gumbart, James C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.